



ADVANCING DRUG DISCOVERY

CRITICAL CHALLENGES FOR LIFE SCIENCES ORGANIZATIONS



Al provides accelerated intelligence and understanding for drug discovery use cases such as genomics, computational chemistry, and structure-based drug design to deliver breakthrough disease treatments.





REVOLUTIONIZING DRUG DISCOVERY WORKFLOWS



HPE and NVIDIA solutions deliver unprecedented drug discovery outcomes, with accelerated time to discovery and improved therapeutics.

33X faster screen of 2B components (1 day vs. 3 months)¹

76x improvement in throughput performance of WGS workflows²

100x improvement screen of 10M drugs (8 minutes versus 240 days)¹ **99.9%** more accurate in precision and sensitivity of WGS analysis²

Supercharged Drug Discovery Enhanced Genomics Research Transformative Therapy Development

Higher Quality of Life

LEARN MORE AT

hpe.com/partners/nvidia hpe.com/us/en/solutions/artificial-intelligence.html

Make the right purchase decision. Contact our presales specialists.



¹NVIDIA COVID-19 case study 2021 ²AI enabled breakthrough genomics, based on HPE internal testing March 2021

© Copyright 2021 Hewlett Packard Enterprise Development LP. The information contained herein is subject to change without notice. The only warranties for Hewlett Packard Enterprise products and services are set forth in the express warranty statements accompanying such products and services. Nothing herein should be construed as constituting an additional warranty. Hewlett Packard Enterprise shall not be liable for technical or editorial errors or omissions contained herein.

NVIDIA, NVIDIA Clara, and the NVIDIA Logo are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. VMware vSphere and VMware are registered trademarks or trademarks of VMware, Inc. and its subsidiaries in the United States and other jurisdictions. All third-party marks are property of their respective owners.

a00119253enw